Table 1.

Characteristics and principal results of recent trials with the Nobori® (Terumo Corporation, Tokyo, Japan) stent as compared with first- and second-generation DESs

Trial	Date	Number of patients	Design of the study and comparator	Longer follow-up available and results
NOBORI CORE54	2008	43 Stable angina 100%	Prospective, multicenter, and comparative. Vasomotion study after implantation of a BES Nobori® stent and an SES	Nine months follow-up. Endothelium-dependent vasomotion is preserved after BES implantation as compared with SES and may reduce thrombotic events.
NOBORI I57	2009	243 UA 28% Stable angina 72%	RCT BES Nobori® stent versus PES Taxus® Liberté	Nine months follow-up. Nobori® stent showed greater degree of neointimal hyperplasia inhibition. Reduction of ISR. No ST up to 9 months.
SORT OUT V59	2013	2,458 STEMI 18% NSTEMI and UA 30% Stable angina 52%	RCT BES Nobori® stent versus first-generation SES Cypher® stent to treat coronary artery stenosis	Twelve months follow-up. BES did not show non-inferiority and did not improve clinical outcomes when compared with SES. Higher early ST in the BES group.
COMPARE II60	2013	2,707 STEMI 22% NSTEMI 27% UA 10% Stable angina 41%	RCT BES Nobori® stent versus second-generation EES Xience® or Prime®	At 12 months follow-up, BES Nobori® stent showed non-inferiority as compared with EES. Procedural failure higher in the BES group.
NEXT61	2013	3,235 STEMI and NSTEMI 5% UA 12% Stable angina 83%	RCT BES Nobori® stent as compared with EES Xience® or Prime®	Twelve months follow-up. Outcome after implantation of BES is non-inferior to EES, with very low rate of ST.

Abbreviations: BES, biolimus-eluting stent; DES, drug-eluting stent; EES, everolimus-eluting stent; ISR, in-stent restenosis; NSTEMI, non-ST-segment elevation myocardial infarction; PES, paclitaxel-eluting stent; RCT, randomized clinical trial; SES, sirolimus-eluting stent; ST, stent thrombosis; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina.